GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group AS (OCSE:PEG) » Definitions » Inventories, Other

Pharma Equity Group AS (OCSE:PEG) Inventories, Other : kr0.00 Mil (As of Dec. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group AS Inventories, Other?

Other inventories including goods for resale, stocks in transit, consignment stocks, etc. Pharma Equity Group AS's other inventories for the quarter that ended in Dec. 2024 was kr0.00 Mil.


Pharma Equity Group AS Inventories, Other Historical Data

The historical data trend for Pharma Equity Group AS's Inventories, Other can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group AS Inventories, Other Chart

Pharma Equity Group AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Other
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharma Equity Group AS Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Other Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pharma Equity Group AS Inventories, Other Calculation

Other inventories including goods for resale, stocks in transit, consignment stocks, etc.


Pharma Equity Group AS Business Description

Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .